BRII BIOSCIENCES LIMITED SUCCESSFULLY LISTED ON HKEX
Latest Update:
13 th July, 2021

On July 13, 2021, Brii Biosciences Limited (hereinafter referred to as "Brii" or the "Company", stock code: 2137.HK), a biotechnology company in China and the United States that promotes therapeutics for major infectious diseases and other diseases with a major public health burden in China and around the world, today listed on the Main board of the Stock Exchange of Hong Kong Limited (" SEHK "). With a market value of more than HK $16 billion, Tengsheng bo reached a peak of HK $23.75 between the plates.

Brii sold 111,580,000 shares globally at the final issue price of HK $22.25 per share, raising a total amount of ABOUT HK $2.482 billion (excluding 16,737,000 shares of green shoes to be exercised).

Tengshengbo is committed to developing innovative therapies for patients with unmet needs and diseases that have a significant public health impact. Through a combination of in-house drug development and licensing, the company has established a pipeline of more than a dozen innovative product candidates for infectious diseases and central nervous system (CNS) diseases, ranging from preclinical to clinical trials. The company is currently advancing the development of therapeutics for major infectious diseases such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensively drug resistant (XDR) Gram-negative bacteria and SARS-COV-2 infection (COVID-19), as well as for CNS disorders. For example, postpartum depression (PPD) and major depressive disorder (MDD).

"The listing on the Stock Exchange of Hong Kong is a very important milestone in the development of Tengsheng Pharma," said Dr. Zhi Hong, Chief Executive Officer of Tengsheng Pharma. We are uniquely positioned for innovative drug development with an outstanding senior management team and experience in multi-regional clinical trials (MRCT). "We will continue to build the r&d pipeline through our internal research and development efforts as well as licensing or partnering with appropriate drug candidates, fulfilling our mission of addressing public health challenges through innovation and insight and benefiting more patients."

It's about Brii Biosciences Limited

Brii Biosciences Limited (" Brii "or the" Company "; Stock Code: 2137.HK) is a biotechnology company based in China and the United States. To promote therapeutics for major infectious diseases (such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensively drug-resistant (XDR) Gram-negative infections) and other diseases (such as central nervous system (CNS) diseases) with a significant public health burden in China and globally. For more information, visit www.briibio.com.

Latest Update:
13 th July, 2021